| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.REGPEP.2006.12.016 |
| P698 | PubMed publication ID | 17276524 |
| P2093 | author name string | H Gutmann | |
| J Drewe | |||
| C Beglinger | |||
| P Schlatter | |||
| P433 | issue | 1-3 | |
| P304 | page(s) | 120-128 | |
| P577 | publication date | 2007-01-10 | |
| P1433 | published in | Regulatory Peptides | Q15762717 |
| P1476 | title | Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells | |
| P478 | volume | 141 |
| Q35138670 | A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor |
| Q41811427 | Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats |
| Q26750746 | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| Q30363683 | Clinical therapeutic strategies for early stage of diabetic kidney disease. |
| Q38315999 | Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications |
| Q64267307 | DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs |
| Q37345603 | Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia |
| Q34690495 | Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney |
| Q37177528 | Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome |
| Q38208950 | Effects of GLP-1 in the kidney |
| Q37232679 | Effects of glucagon-like peptide-1 receptor agonists on renal function |
| Q37696496 | Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials |
| Q37995767 | Food preferences and aversions in human health and nutrition: how can pigs help the biomedical research? |
| Q38709406 | GLP-1 Agonists and Blood Pressure: A Review of the Evidence. |
| Q97644233 | GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms |
| Q50225916 | GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes |
| Q36406821 | GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. |
| Q39164330 | Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure |
| Q39604870 | Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes |
| Q90065432 | Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel |
| Q36527908 | Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. |
| Q35160068 | Gut sensing of dietary K⁺ intake increases renal K⁺excretion |
| Q102220349 | Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence |
| Q26739999 | Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence |
| Q38236209 | Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. |
| Q43742584 | Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial |
| Q58772377 | Liraglutide relieves cardiac dilated function than DPP-4 inhibitors |
| Q38213048 | Microinflammation in the pathogenesis of diabetic nephropathy |
| Q89052824 | Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA |
| Q37635255 | Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. |
| Q36312680 | Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice |
| Q26777994 | Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? |
| Q47099705 | Novel Therapies for Acute Kidney Injury |
| Q41604037 | One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. |
| Q34062829 | Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system |
| Q46196926 | Protection of exendin-4 analogue in early experimental diabetic retinopathy |
| Q30390165 | Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. |
| Q52321766 | Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes. |
| Q37581754 | Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study |
| Q46770322 | Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin |
| Q34647984 | Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q90416951 | The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes |
| Q33866808 | The evolving place of incretin-based therapies in type 2 diabetes |
| Q38174491 | The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? |
| Q38227648 | The potential for renoprotection with incretin-based drugs |
Search more.